Navigation Links
ATOLL Study Results With Intravenous Enoxaparin in Acute Heart Attack Managed with Urgent Angioplasty
Date:8/30/2010

ATOLL Study Results With Intravenous Enoxaparin in Acute Heart Attack Managed with Urgent... -- PARIS, August 30, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Clinical Trials & Medical Discoveries Click to view news release full screen  

ATOLL Study Results With Intravenous Enoxaparin in Acute Heart Attack Managed with Urgent Angioplasty

 

PARIS, August 30, 2010 /PRNewswire/ --

- Composite Primary Endpoint: Risk Reduction of 17% (Non-Statistically Significant ) in Death, Complication of Myocardial Infraction, Procedure Failure or Major Bleeding (p=0.07)

- Main Secondary Composite Efficacy Endpoint: 40% Reduction of Death, Recurrent Acute Coronary Syndrome or Re-Intervention (p=0.01)

Pitie-Salpetriere Hospital, Paris, France, August 30th 2010. The international ATOLL study sponsored by the Assistance Publique - Hopitaux de Paris showed that enoxaparin reduced the composite of death, complication of myocardial infraction, procedure failure or major bleeding by 17% in comparison with standard heparin (p=0.07) in acute heart-attack (STEMI) patients managed with primary Percutaneous Coronary Intervention (PCI). The pre-specified main secondary efficacy endpoint showed that treatment with enoxaparin resulted in a statistically significant 40% reduction of patients' death, recurrent acute coronary syndrome or urgent revascularisation. The results of the ATOLL study were presented at the hotline session of the annual European Cardiology Congress (ESC 2010) in Stockholm, Sweden.

As a result of acute heart attack (STEMI), overall one third of patient may die in the first 24 hours after the onset of the ischemic symptoms, making patients' access to appropriate care units critical. In real life mortality remains high with up to a 10 % death rate at 30 days.

'With all the "hard" pre-specified ischemic and death related endpoints favoring enoxaparin over UFH, enoxaparin becomes a new alternative in primary PCI', said Prof. Gilles Montalescot, Head of Cardiac Care Unit (CCU) at Pitie-Salpetriere Hospital in Paris and lead investigator of the ATOLL study. 'By allowing maintenance of the same anticoagulant throughout patient management from the emergency room or the ambulance to the catheterization laboratory then to the Cardiac Care Unit, without anticoagulation monitoring, enoxaparin is securing and simplifying the treatment strategy' he added.

The international ATOLL study sponsored by the Assistance Publique - Hopitaux de Paris enrolled 910 patients suffering from ST-elevated Myocardial Infraction (STEMI), the most severe form of heart attack. Patients received either intravenous administration of 0.5 mg/kg enoxaparin (Clexane/Lovenox(R)) without anticoagulation monitoring/dose adjusted or standard UFH (unfractionated heparin) prior to primary Percutaneous Coronary Intervention, a procedure also referred as angioplasty and stenting.

With regard to major bleeding risk, the main safety endpoint, no difference was observed in the two treatment groups (respectively 4.9% and 4.5% for UFH and enoxaparin). The same observation was reported with minor bleeding risk (8.9% with UFH and 7% with enoxaparin).

About ATOLL

The ATOLL (Acute STEMI Treated with primary angioplasty and intravenous enoxaparin Or UFH to Lower ischemic and bleeding events at short and Long-term follow-up) study is the first randomised, head-to-head comparison between unfractionated heparin (UFH) and Clexane/Lovenox(R) (enoxaparin) in primary angioplasty in subjects with ST-segment elevation myocardial infarction (STEMI). The ATOLL study included 910 subjects from 31 sites in several countries including Austria, France, Germany and the United States. Patients were randomized within 24 hours of symptom onset to receive either UFH IV bolus (ACT-adjusted), 50-70IU with concurrent GP IIb/IIIa treatment or 70-100IU without GP IIb/IIIa treatment, or Clexane/Lovenox(R) (enoxaparine) 0.50 mg/kg IV bolus without monitoring. The ATOLL study is sponsored by AP-HP (Assistance Publique-Hopitaux de Paris) and received funding from AP-HP, in addition to an unrestricted research grant from sanofi-aventis.

About ST-elevation-myocardial infarction (STEMI)

STEMI is one of the most serious and one of the most deadly types of heart attacks characterized by an abrupt, complete blockage of a coronary artery. It leads to irreversible myocardial damage as a result of insufficient blood supply to the heart muscle (or myocardial ischemia). STEMI is usually recognized by an elevation of the ST segment on the ECG, indicating that a large amount of heart muscle damage is occurring.

About primary Percutaneous Coronary Intervention (PCI)

Primary PCI, often referred to as primary angioplasty, involves opening the artery using a small balloon to clear the blockage. During the procedure, a catheter is threaded through an artery up through the blood vessel to the area in the coronary artery that is blocked. A small balloon at the tip of the catheter is inflated to widen the blood vessel and restore blood flow to the heart. Often a small metal mesh tube called a stent is placed in the artery to keep it open.


'/>"/>
SOURCE Assistance Publique - Hopitaux de Paris
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
2. RAND study finds increase in piracy and terrorism at sea
3. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
4. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
5. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
6. Video: CSL Behring Provides $1.2M Grant for Worlds First Study of Postpartum Women with VWD, Common Bleeding Disorder
7. RainDance and Scripps to Collaborate on Targeted Sequencing for Wellderly Study
8. Preliminary Report of American Biotech Labs HIV Study Featured in Inaugural Issue of Journal of the Science of Healing Outcomes
9. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
10. ESBATech Announces Successful Completion of Phase I Clinical Study for Lead Antibody Fragment in Ophthalmic Indications
11. Germicidal UVC Lights Improve Clinical Pregnancy Rates for IVF Lab, New Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016  Regular discussions on a range of subjects including ... two entities said Poloz. Speaking at a lecture ... , he pointed to the country,s inflation target, which is ... "In certain areas there ... common economic goals, why not sit down and address strategy ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced ... this eBook by providing practical tips, tools, and strategies for clinical researchers. , ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
Breaking Biology Technology:
(Date:6/16/2016)... , June 16, 2016 ... is expected to reach USD 1.83 billion by ... View Research, Inc. Technological proliferation and increasing demand ... are expected to drive the market growth. ... The development of advanced multimodal techniques ...
(Date:6/7/2016)... June 7, 2016  Syngrafii Inc. and San ... relationship that includes integrating Syngrafii,s patented LongPen™ eSignature ... This collaboration will result in greater convenience for ... union, while maintaining existing document workflow and compliance ... ...
(Date:6/2/2016)... June 2, 2016 Perimeter Surveillance ... Unmanned Systems, Physical Infrastructure, Support & Other Service  ... visiongain offers comprehensive analysis of the global ... will generate revenues of $17.98 billion in 2016. ... Inc, a leader in software and hardware technologies for ...
Breaking Biology News(10 mins):